Introduction:
Nitrosamine control in continuous manufacturing is one of the most pressing quality and regulatory challenges facing pharmaceutical manufacturers today. Unlike traditional batch manufacturing, continuous manufacturing (CM) processes involve uninterrupted material flow, recirculated solvents, and longer equipment residence times — all of which can amplify the formation and accumulation of potentially genotoxic nitrosamine impurities.
Since the landmark recalls triggered by nitrosamine contamination in sartan and ranitidine products (2018–2020), regulatory agencies including the FDA, EMA, and Health Canada have issued binding guidance requiring manufacturers to proactively assess and control nitrosamine risks across their entire manufacturing process. For companies operating continuous manufacturing lines, this is not a simple checkbox exercise — it requires a fundamentally different control philosophy.
At ResolveMass Laboratories Inc., we have partnered with pharmaceutical clients across North America to design and implement rigorous, science-driven nitrosamine control strategies tailored specifically to the complexities of continuous manufacturing. This case study documents the approach, methodology, and outcomes of one such implementation.
Summary:
- Nitrosamine control in continuous manufacturing requires a proactive, risk-based strategy covering raw materials, process chemistry, and equipment design.
- ICH M7(R2) and FDA/EMA nitrosamine guidance form the regulatory backbone for any acceptable control strategy.
- Continuous manufacturing (CM) introduces unique nitrosamine risks not present in batch processing — particularly from prolonged equipment residence times, recycled solvents, and in-line mixing.
- A structured Nitrosamine Risk Assessment (NRA) is the essential first step before any analytical or engineering control is implemented.
- Real-time PAT (Process Analytical Technology) monitoring can serve as a powerful nitrosamine detection and control tool in CM environments.
- ResolveMass Laboratories Inc. has successfully supported pharmaceutical manufacturers in designing, validating, and implementing compliant nitrosamine control strategies.
1: What Are Nitrosamines and Why Are They a Regulatory Concern?
Nitrosamines are a class of N-nitroso compounds, many of which are classified as probable human carcinogens. They can form in drug substances and drug products through several mechanisms:
- Reaction between secondary amines and nitrosating agents (e.g., nitrite residues, nitrogen oxides)
- Degradation of nitrogen-containing excipients or APIs under heat, humidity, or acidic conditions
- Contamination from raw materials, starting materials, or reagents used in synthesis
- Cross-contamination from equipment — especially in shared manufacturing lines
Regulatory agencies have established strict Acceptable Intake (AI) limits for known nitrosamines. Key regulatory thresholds include:
| Nitrosamine | Acceptable Intake (AI) Limit | Potency Category (ICH M7) |
|---|---|---|
| NDMA (N-Nitrosodimethylamine) | 96 ng/day | Cohort of concern |
| NDEA (N-Nitrosodiethylamine) | 26.5 ng/day | Cohort of concern |
| NMBA (N-Nitrosomethylbenzylamine) | 96 ng/day | Category 1 |
| NDIPA (N-Nitrosodiisopropylamine) | 26.5 ng/day | Category 1 |
| NDBA (N-Nitrosodibutylamine) | 26.5 ng/day | Category 1 |
| Non-cohort nitrosamines (calculated) | Based on TTC (1,500 ng/day) | Category 2–5 |
Source: ICH M7(R2) and FDA/EMA Nitrosamine Guidance Documents
For continuous manufacturing, where product is generated over extended operating windows, even trace formation rates can result in unacceptable cumulative contamination if not identified and controlled early.
2: Understanding the Unique Nitrosamine Risks in Continuous Manufacturing
Continuous manufacturing differs fundamentally from batch processing in ways that directly affect nitrosamine risk. The key CM-specific risk factors include:
- Prolonged equipment exposure: In a continuous process, material is in contact with equipment surfaces, lubricants, and gaskets for significantly longer periods, increasing the potential for contamination from nitrosating agents present in materials of construction.
- Recycled solvent streams: Solvents recovered and recirculated within the process may concentrate trace nitrosamines or nitrosating agents over multiple cycles if not monitored.
- In-line mixing and reaction zones: Real-time mixing of amine-containing APIs or intermediates with potentially nitrosating co-reagents creates dynamic formation risk windows that are absent in discrete batch steps.
- Steady-state transitions: During start-up, shut-down, and process upsets, the chemical environment in a continuous reactor can temporarily shift in ways that favor nitrosamine formation.
- Integrated unit operations: The tight coupling of reaction, crystallization, filtration, and drying in CM means that a nitrosamine formed upstream can rapidly propagate into downstream product without the natural hold-and-test points available in batch processing.
Step 1: Conducting a Nitrosamine Risk Assessment (NRA) for a Continuous Process
The first step in any nitrosamine control strategy is a thorough, documented risk assessment. A CM-specific NRA should answer these questions upfront:
- Are there secondary or tertiary amines present in the API synthesis or formulation?
- Are there nitrosating agents (nitrite salts, nitrogen oxides, nitric acid) present or potentially generated at any process step?
- What are the temperature, pH, and residence time conditions at each unit operation?
- Are there degradation pathways for any excipient or packaging material that could generate nitrosamines?
- Are shared equipment lines a potential source of cross-contamination?
ResolveMass Laboratories’ NRA Framework for Continuous Manufacturing:
| Risk Assessment Element | CM-Specific Consideration | Output |
|---|---|---|
| Amine mapping | Identify all amines across the continuous flow scheme | List of potential nitrosamine precursors |
| Nitrosating agent survey | Include recycled solvents, inert gas streams (N₂ purity), equipment lubricants | Risk-ranked source list |
| Process condition modeling | Model temperature/pH profiles at steady state and during transitions | Critical risk windows |
| Equipment materials review | Assess gaskets, seals, filters for N-nitroso leachables | Leachable risk profile |
| Worst-case formation modeling | Apply kinetic data to estimate formation potential at AI threshold | Go/no-go for further controls |
The NRA is not a one-time document. In a continuous manufacturing context, it must be treated as a living assessment that is updated whenever process parameters, raw material sources, or equipment components change.
Step 2: Establishing Analytical Methods for Nitrosamine Detection in CM
Once risk pathways have been identified, validated analytical methods must be in place before any control strategy can be deemed effective. For CM, this introduces the additional challenge of enabling real-time or near-real-time detection.
Key analytical approaches used by ResolveMass Laboratories:
- LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry): The gold standard for nitrosamine quantification at ppb-level concentrations. Used for method development, validation (per ICH Q2(R2)), and periodic verification sampling in CM lines.
- GC-MS/MS (Gas Chromatography-Tandem Mass Spectrometry): Preferred for volatile nitrosamines such as NDMA and NDEA where headspace extraction improves sensitivity and throughput.
- HPLC-UV/Vis: Suitable for higher-concentration screening applications, particularly for monitoring nitrite levels as a proxy for nitrosation risk upstream.
- PAT Integration (In-line/At-line): In-line NIR or Raman spectroscopy can detect changes in process chemistry that correlate with nitrosamine formation risk, enabling proactive intervention without halting the process.
Method Validation Requirements (per ICH Q2(R2) and FDA Guidance):
| Validation Parameter | Requirement for Nitrosamine Methods |
|---|---|
| Specificity | Demonstrate no interference from API matrix, excipients, or degradants |
| LOD / LOQ | Must be ≤ 30% of the AI-based specification limit |
| Linearity | Across at least 50–150% of the specification limit |
| Accuracy (Recovery) | 80–120% across all spiked concentration levels |
| Precision (RSD) | ≤ 15% at LOQ; ≤ 10% at working concentration |
| Stability | Demonstrate stability of nitrosamines in solution and in extracted matrix |
At ResolveMass Laboratories, our analytical team has developed and validated over 20 nitrosamine methods across diverse API matrices, including for complex continuous manufacturing platforms where matrix variability across the production window is a significant analytical challenge.
Step 3: Implementing Engineering and Process Controls
With risk pathways identified and analytical methods validated, the next phase involves implementing specific controls to prevent nitrosamine formation or ensure their removal below AI limits.
Engineering Controls in Continuous Manufacturing:
- Nitrogen gas purity specifications: Mandate ≥ 99.999% purity (Grade 5.0) inert gas to eliminate NOₓ as a nitrosating agent in reactors and storage vessels.
- Equipment material substitution: Replace incompatible gasket materials (e.g., certain rubbers containing N-nitrosamine-releasing accelerators) with FDA-compliant PTFE or stainless-steel alternatives.
- Dedicated equipment lines: For high-risk amine APIs, implement dedicated continuous manufacturing equipment to eliminate cross-contamination risk from shared lines.
- Solvent recovery quality gates: Install inline monitoring checkpoints for recycled solvent streams, with automatic diversion if nitrosating agent levels exceed action thresholds.
Process Chemistry Controls:
- pH adjustment: Control reaction pH to minimize nitrosamine formation kinetics, particularly in crystallization and workup steps where amine and nitrite species may co-exist.
- Scavenger addition: Introduce food-grade ascorbic acid or similar nitrosation inhibitors at identified risk windows to competitively consume nitrosating agents before they can react with amines.
- Temperature profiling: Redesign process flow to minimize the duration of high-temperature exposure steps where nitrosamine formation rates are elevated.
Procedural Controls:
- Supplier qualification and incoming raw material testing for nitrosamines and nitrosating agents
- Routine cleaning validation studies demonstrating removal of nitrosamine residues from CM equipment
- Real-time process monitoring alarm limits linked to nitrosamine formation proxy parameters (pH, temperature, NOₓ concentration)
Step 4: Real-Time PAT Monitoring as a Control Strategy Element
Real-time monitoring is where continuous manufacturing genuinely excels over batch in the context of nitrosamine control. By integrating PAT tools into the CM line, it becomes possible to detect process deviations that correlate with nitrosamine formation risk — and to intervene before out-of-specification product is generated.
ResolveMass Laboratories’ PAT Integration Framework:
- In-line UV/Vis or Raman spectrometers positioned after each reactor unit to monitor for spectroscopic changes associated with nitrosation chemistry
- Process mass spectrometry for real-time NOₓ monitoring in reactor headspace
- Automated feedback control loops that trigger pH adjustment or scavenger dosing when formation-risk parameters exceed pre-set limits
- Data integration with the manufacturing execution system (MES) to ensure full batch record traceability for each product interval across the continuous process window
This PAT-driven approach transforms nitrosamine control from a reactive, end-product-testing paradigm to a proactive, in-process quality assurance system — exactly the model that FDA’s Process Analytical Technology guidance and ICH Q13 (Continuous Manufacturing) envision.
Step 5: Regulatory Documentation and Submission Strategy
A technically sound control strategy is only effective if it is properly documented for regulatory review. For continuous manufacturing, this means aligning nitrosamine control documentation with both ICH Q13 requirements and jurisdiction-specific nitrosamine guidance.
Key regulatory documents required:
- Nitrosamine Risk Assessment report (referenced in the drug substance and drug product dossier)
- Analytical method validation reports meeting ICH Q2(R2) standards
- Control Strategy Document describing all engineering, process, and analytical controls as an integrated system
- Change Management Protocol outlining the NRA update process for any manufacturing change
- Regulatory Health Canada / FDA correspondence records if confirmatory testing or enhanced scrutiny has been triggered
ResolveMass Laboratories provides end-to-end regulatory support, from drafting NRA narratives and CMC sections to preparing responses to agency queries on nitrosamine data packages.
3: Outcomes and Key Learnings from the ResolveMass Case Study
Following full implementation of the nitrosamine control strategy described above in a client’s continuous API manufacturing process, the following outcomes were achieved:
- 100% compliance with FDA and Health Canada nitrosamine limits across all commercial production intervals
- Zero nitrosamine OOS (Out-of-Specification) events in the 18 months following strategy implementation
- Reduction in end-product nitrosamine testing frequency by 40%, enabled by validated in-process controls and PAT monitoring, resulting in cost savings
- Successful Type II Variation approval (EMA) and Prior Approval Supplement (FDA) for the updated control strategy
- Accelerated regulatory review attributed to the structured, science-backed documentation package prepared by ResolveMass
These results demonstrate that a well-designed nitrosamine control strategy in continuous manufacturing does not just ensure compliance — it actively improves process understanding, reduces quality risk, and can deliver operational efficiencies.
Conclusion:
Nitrosamine control in continuous manufacturing represents both a regulatory obligation and an opportunity to demonstrate the highest standards of pharmaceutical quality. As continuous manufacturing becomes the preferred mode for new drug development and commercial production, the ability to implement robust, validated, and ICH-aligned nitrosamine control strategies will increasingly differentiate compliant, efficient manufacturers from those who face costly remediation and regulatory action.
ResolveMass Laboratories Inc. brings deep expertise in ICH M7, ICH Q13, FDA nitrosamine guidance, and pharmaceutical analytical chemistry to help you build a nitrosamine control program that is scientifically rigorous, regulatory-ready, and operationally sustainable — whether you are developing a new CM process or remediating an existing one.
Our team has supported clients through Health Canada, FDA, and EMA submissions and has a proven track record of delivering compliant, approved nitrosamine control strategies for complex continuous manufacturing platforms.
Frequently Asked Questions:
Nitrosamines can form when nitrites or other nitrosating agents react with secondary or tertiary amines under specific manufacturing conditions. Factors such as solvent recycling, elevated temperatures, extended residence times, contaminated raw materials, and process variability can contribute to nitrosamine formation if appropriate controls are not in place.
Common sources include contaminated raw materials, excipients containing nitrites, degraded solvents, catalysts, and process water impurities. Recycled solvents may also accumulate nitrosamine precursors over time if not properly managed. Packaging components and manufacturing equipment can occasionally contribute to contamination risks. Comprehensive supplier qualification and incoming material testing help identify potential sources early. Effective control measures can significantly reduce contamination risks.
Real-time monitoring provides immediate visibility into critical process parameters that could influence nitrosamine formation. It allows manufacturers to detect deviations before they impact product quality. Continuous monitoring supports faster decision-making and corrective actions. This proactive approach reduces process variability and improves manufacturing efficiency. It also strengthens compliance with regulatory expectations for process control and quality assurance.
Solvent recovery systems can concentrate trace impurities such as nitrites during repeated recycling cycles. Over time, these impurities may reach levels that increase the likelihood of nitrosamine formation. If susceptible amine-containing compounds are present, the risk becomes greater. Proper purification, monitoring, and replacement schedules help prevent impurity accumulation. Regular testing of recovered solvents is an important part of an effective control strategy.
An effective strategy includes risk assessment, supplier qualification, raw material testing, process optimization, and analytical monitoring. It also incorporates real-time process controls and validation studies to confirm effectiveness. Manufacturers should establish ongoing lifecycle management programs to address emerging risks. Multiple layers of control help reduce the likelihood of nitrosamine formation. Together, these measures support product quality and regulatory compliance.
No, ICH M7(R2) does not specifically focus on continuous manufacturing. Instead, it provides a risk-based framework for assessing and controlling mutagenic impurities, including nitrosamines, across all pharmaceutical manufacturing processes. The principles outlined in ICH M7(R2) apply equally to batch and continuous manufacturing systems. Manufacturers using continuous processes must adapt these principles to account for unique operational factors such as continuous material flow, real-time process monitoring, and extended production campaigns. Compliance requires demonstrating that impurity risks are effectively identified, assessed, and controlled throughout the product lifecycle.
The most common source of nitrosamine contamination in continuous manufacturing is the presence of nitrite impurities in raw materials, solvents, excipients, or recycled process streams. When these nitrites interact with secondary or tertiary amines under suitable process conditions, nitrosamines can form. Solvent recovery systems may further increase risk by concentrating trace nitrite impurities over time. Other contributing factors include contaminated process water, degraded reagents, and supplier-related variability. A comprehensive risk assessment is essential to identify and control these potential sources before they impact product quality.
No, end-product testing alone is generally not considered sufficient for effective nitrosamine control. While final product testing can confirm whether nitrosamines are present, it does not prevent their formation during manufacturing. Regulatory agencies increasingly expect manufacturers to implement proactive, risk-based control strategies that address nitrosamine risks at the source. This includes raw material screening, process optimization, supplier qualification, in-process monitoring, and analytical verification. A comprehensive control program provides greater assurance of product quality, patient safety, and long-term regulatory compliance than relying solely on end-product testing.
Reference
- Urquhart MW, Burns MJ, Bernardoni F, Clark HF, Crochard JP, De Benedetti A, Dirat O, Fennell JW, Gall MA, Galli M, Hildbrand S. Industrial Case Studies Demonstrating Applicability of ICH M7 Control Options 3 and 4 for Nitrosamine Control. Organic Process Research & Development. 2025 Mar 21;29(4):1152-67.https://pubs.acs.org/doi/abs/10.1021/acs.oprd.5c00042
- Badia L, Camps H, Lloveras I, Handler N, Buschmann H, Valls J, Poznik M. Strategy to Assess and Control Nitrosamine Formation in API during Storage: A Sitagliptin Case Study. Organic Process Research & Development. 2024 Aug 6;28(8):3182-96.https://pubs.acs.org/doi/abs/10.1021/acs.oprd.4c00088
- Dirat O, Urquhart MW, Akehurst H, Burns MJ, Dobo KL, Harvey J, Kuhl N, Schlingemann J, Tomlin P, Wetter C. Drug substance and drug product workflows for quality risk management for the presence of nitrosamines in medicines. Organic Process Research & Development. 2025 May 23;29(6):1538-53.https://pubs.acs.org/doi/abs/10.1021/acs.oprd.5c00097
- Yerram S, Muhammad Nizam VP, Srivastava S, Nanduri S. Nitrosamine Contamination in Pharmaceuticals: A Retrospective Regulatory Analysis of USFDA Recalls and Risk Mitigation Strategies (2018–2025). Therapeutic Innovation & Regulatory Science. 2026 Mar;60(2):519-33.https://link.springer.com/article/10.1007/s43441-025-00891-y
- Cioc RC, Joyce C, Mayr M, Bream RN. Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies. Organic Process Research & Development. 2023 Jul 21;27(10):1736-50.https://pubs.acs.org/doi/abs/10.1021/acs.oprd.3c00153
- Pinnamraju N, Hemadurga S. A Review on Nitrosamine Impurities in Pharmaceutical Products. Journal of Pharma Insights and Research. 2025 Oct 5;3(5):068-77.https://jopir.in/index.php/journals/article/view/548
About the Author
